{
  "ticker": "OSL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02977924",
  "id": "02977924",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250807",
  "time": "1006",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250807/pdf/06mmn3tbxwxk31.pdf",
  "summary": "**Summary of ASX Announcement (OncoSil Medical Limited \u2013 07 August 2025):**  \n\n- **Investor Webinar**: Discussion of key commercialisation milestones, including:  \n  - Record OncoSil\u2122 dose sales in Q4 FY25.  \n  - Expansion plans (new regions, including the US).  \n  - Clinical study by German Federal Joint Committee (G-BA) pending.  \n  - Allocation of **$8.7M capital raise** proceeds (recently completed).  \n\n**No material trading/capital markets actions disclosed.** (Announcement is informational only.)  \n\n*Omitted:* Operational details, webinar logistics, background company info.",
  "usage": {
    "prompt_tokens": 1227,
    "completion_tokens": 141,
    "total_tokens": 1368,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-07T01:53:04.496039"
}